海角视频

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Enterprise

Newcastle's AMLo Biosciences ramps up fight against skin cancer with 拢1.6m investment

The Newcastle life sciences pioneer's first product has the potential to save thousands of lives every year as well as reassure thousands of others

Researchers in the AMLo lab who have helped produce a cutting-edge new skin cancer test(Image: Newcastle University)

A Newcastle life sciences company specialising in early-stage skin cancer testing is ramping up its potentially life-saving work with a £1.6m investment.

AMLo Biosciences Ltd (AMLo) was first launched at Newcastle University five years ago and has developed a diagnostic test called AMBLor – a simple test which allows clinicians to ascertain whether early-stage melanomas are at low-risk of progression. The innovative medical device has the potential to save thousands of lives every year as well as reassure thousands of others that their early stage skin cancer will not progress.

By using the test, the level of urgency in cases can be worked out, meaning patients at genuine risk can be prioritised and those with lower risk won’t endure anxiety. The team behind AMBLor have highlighted how the test has significant benefits in terms of both the cost and effectiveness of freeing up appointments and healthcare workers’ time whilst wasting fewer medical resources involving invasive procedures.

Now the innovative test producer has been given a boost of £800,000 from the North East Innovation Fund supported by the European Regional Development Fund, managed by Northstar Ventures, which has been matched by Esperante Ventures, completing a total funding round of £1.6m.

The company has recently gained the 海角视频CA mark for the AMBLor test which means the kit can now be used throughout the 海角视频 in public and private healthcare systems. The company is also operating in the US, with the potential to take the product out to the global market.

Marie Labus, CEO, AMLo Biosciences, said: “The AMLo executive team recognises the confidence that Northstar Ventures has in the whole team and AMLo’s technology with the initial and subsequent investment support since 2018. At the point at which our USA launch is just starting to take off and we are seeing real interest from the 海角视频, this investment means that we can start to build the company further into growth.”

Northstar Ventures said the funding supports AMLo’s drive to find solutions to the challenges cancer patients face.

Dr Alex Buchan, investment director at Northstar Ventures, said: “We have supported AMLo since the company’s inception in 2018, an indication of how strongly we are committed to their aim to alleviate the challenges faced by the medical profession and provide better outcomes for melanoma sufferers.